basal cell carcinoma: Disease Detail - Cancer Knowledgebase (CKB)

Profile Responses 2
Clinical Trials 48

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 2 of 2 entries

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail
BRAF V600E	Dabrafenib + Trametinib	basal cell carcinoma	predicted - sensitive	detail...
KDR R1032Q	Pazopanib	basal cell carcinoma	predicted - sensitive	detail...

Showing 1 to 2 of 2 entries

Filter rows:

Showing 1 to 48 of 48 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02978625	Phase II	Nivolumab + Talimogene laherparepvec	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Active, not recruiting	USA	0
NCT03816332	Phase I	Ipilimumab + Nivolumab + Prednisone + Tacrolimus	Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers	Active, not recruiting	USA	0
NCT04323202	Phase I	Pembrolizumab	Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N	Active, not recruiting	USA	0
NCT05859074	Phase I	MQ710 + Pembrolizumab MQ710	A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Active, not recruiting	USA	0
NCT01367665	Phase II	Vismodegib	STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma	Completed	TUR \| SWE \| SVN \| SVK \| ROU \| POL \| NZL \| NOR \| NLD \| LTU \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	6
NCT01543581	Phase II	Vismodegib	Vismodegib for Treatment of Basal Cell Carcinoma (Erivedge)	Completed		0
NCT01700049	Phase II	Vismodegib	Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes	Completed	USA	0
NCT01815840	Phase II	Vismodegib	A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| AUT	2
NCT02120677	Phase I	Itraconazole	Topical Itraconazole in the Treatment of Basal Cell Carcinoma	Completed	USA	0
NCT02436408	FDA approved	Vismodegib	VISmodegib for ORbital and Periocular Basal Cell Carcinoma	Completed	USA	0
NCT02639117	Phase I	Vismodegib	Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas	Completed	USA	0
NCT02690948	Phase II	Pembrolizumab + Vismodegib Pembrolizumab	Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer	Completed	USA	0
NCT02735356	Phase I	Itraconazole	Topical Itraconazole in Treating Patients With Basal Cell Cancer	Completed	USA	0
NCT03132636	Phase II	Cemiplimab	PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy	Completed	USA \| ITA \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUT	0
NCT03517488	Phase I	XmAb20717	A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)	Completed	USA	0
NCT03610022	FDA approved	Vismodegib	Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 (OPTIVISMO-1)	Completed	FRA	0
NCT03897036	Phase I	Silmitasertib	Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	Completed	USA	0
NCT04089527	Phase I	FT-1101	Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma	Completed	FRA \| ESP	0
NCT04416516	Phase II	ASN002	Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor	Completed	AUS	0
NCT04669808	Phase II	Cotsiranib	Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma	Completed	USA	0
NCT04925713	Phase I	IFx-Hu2.0	IFx-Hu2.0 for the Treatment of Patients With Skin Cancer	Completed	USA	0
NCT05188729	Phase II	LTX-315	Open-Label Proof of Concept Study of LTX-315 in Basal Cell Carcinoma	Completed	USA	0
NCT05713760	Phase II	KX2-391	Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults	Completed	USA	0
NCT06624475	Phase II	Nivolumab and relatlimab-rmbw Nivolumab	Neoadjuvant Opdualag Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma	Not yet recruiting	USA	0
NCT03521830	Phase II	Nivolumab Ipilimumab + Nivolumab	Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma	Recruiting	USA	0
NCT03534947	Phase II	Imiquimod + Sonidegib Sonidegib	A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma (SONIB)	Recruiting	AUS	0
NCT03767348	Phase Ib/II	Nivolumab + RP1 RP1	Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)	Recruiting	USA \| GBR \| FRA \| ESP \| DEU	0
NCT04349436	Phase Ib/II	RP1	A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS)	Recruiting	USA	0
NCT04362722	Phase II	Daromun	Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients (DUNCAN)	Recruiting	POL \| DEU \| CHE	0
NCT04806646	Phase II	Sonidegib	Tailored Sonidegib Schedule After Complete Response in BCC (SONIBEC)	Recruiting	ITA	0
NCT05086692	Phase Ib/II	MDNA11 + Pembrolizumab	A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)	Recruiting	USA \| IRL \| ESP \| CAN \| AUS	2
NCT05329792	Phase II	Daromun	L19IL2/L19TNF in Skin Cancer Patients	Recruiting	ITA \| FRA \| ESP	0
NCT05533697	Phase Ib/II	mRNA-4359 + Pembrolizumab mRNA-4359	Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors	Recruiting	USA \| GBR \| ESP \| AUS	0
NCT05651828	Phase I	Vismodegib	Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma	Recruiting	USA	0
NCT05896839	Phase Ib/II	Ipilimumab + Nivolumab + Prednisone + Sirolimus	Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	Recruiting	USA	0
NCT05929664	Phase II	Cemiplimab	Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery	Recruiting	USA	0
NCT06112522	Phase II	KX2-391	Tirbanubulin (Klisiry) in the Treatment of Basal Cell Carcinoma	Recruiting	FRA	0
NCT06344052	Phase II	Vismodegib SP-002 + Vismodegib	To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma	Recruiting	USA	0
NCT06409195	Phase II	SM-020	A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers	Recruiting	USA	0
NCT06422936	Phase II	BO-112	Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) (SPOTLIGHT204)	Recruiting	ISR \| ESP	0
NCT06514651	Phase I	MAQ-001 Ipilimumab + MAQ-001	MAQ-001 in Patients With Advanced Solid Tumors	Recruiting	FRA	0
NCT07010692	Phase Ib/II	KX2-391	Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment	Recruiting	USA	0
NCT01898598	Phase II	Vismodegib	A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma	Terminated	USA	0
NCT02067104	Phase II	Vismodegib	Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention	Terminated	USA	0
NCT02303041	Phase I	Buparlisib + Sonidegib	Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma	Terminated	USA	0
NCT03220347	Phase I	CC-90010	A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas	Terminated	ITA \| FRA \| ESP	1
NCT04155190	Phase II	Patidegib topical gel	An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC	Terminated	USA	0
NCT02699723	Phase I	Arsenic trioxide + Itraconazole	Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer	Withdrawn		0

Showing 1 to 48 of 48 entries

Filter rows:

ID	DOID:2513
Name	basal cell carcinoma
Definition	A skin carcinoma affecting basal cells.
Source	DiseaseOntology.org
Alt Ids	DOID:4275 DOID:4276
Path	disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin carcinoma basal cell carcinoma

basal cell carcinoma
Disease Detail

Contact

Filtering

Sorting

basal cell carcinomaDisease Detail

Contact

Filtering

Sorting

basal cell carcinoma
Disease Detail